tiprankstipranks

Bvf Partners LP Il Insider Profile

326 Followers
Bvf Partners LP Il, See Explanation of Responses at ChemoCentryx, holds 87.91K shares in 4D Molecular Therapeutics (Ticker: FDMT), holds 176.69K shares in Third Harmonic Bio, Inc. (Ticker: THRD), holds 1.29M shares in MoonLake Immunotherapeutics (Ticker: MLTX).
tipranks
Bvf Partners LP Il

Bvf Partners LP Il
ChemoCentryx (CCXI)
See Explanation of Responses

Ranked #22 out of 99,335 Corporate Insiders

Profitable Transactions

63%
89 out of 141 Profitable Transactions

Average Return

+51.50%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark

Insider Holdings

$4B
36.83%
26.75%
8.45%
5.34%
22.64% Others
A breakdown of Bvf Partners LP Il's holdings

Insider Roles

Repligen
(RGEN)
Indirect Beneficial Owner, Ten Percent Owner
Neurocrine
(NBIX)
See Explanation of Responses
Cytokinetics
(CYTK)
See Explanaton of Responses
Kymera Therapeutics
(KYMR)
Director, See Remarks and Footnotes
+24 other positions
Roles that Bvf Partners LP Il holds in companies

Most Profitable Insider Trade

Stock:
Five Prime Therapeutics
(FPRX)
Rating:Informative Buy
Date:Nov 26, 2019 - Nov 26, 2020
Return:+467.90%
The most profitable trade made by Bvf Partners LP Il

Bvf Partners LP Il's Trading History

Company Name
Last Transaction Date
Insider Position
Last Transaction
Last Transaction Amount
Holding Value
CCXI
ChemoCentryx
Nov 05, 2015
Uninformative Sell
$177.51M
CTIC
CTI BioPharma
Jun 28, 2023
Uninformative Sell
80.59M
$0.00
Xenon
Mar 29, 2018
Ten Percent Owner
Uninformative Sell
$2.34M
Infinity Pharmaceuticals
Feb 16, 2021
See Explanation of Responses
Informative Sell
12.11M
$132.21K
Xoma
Jan 09, 2023
Director, See Remarks, Ten Percent Owner
Informative Buy
420.63K
$115.44M
GlycoMimetics
Nov 06, 2020
Ten Percent Owner
Informative Buy
3.29M
$208.05K
CNCE
Concert Pharma
Jun 12, 2019
Informative Sell
4.13M
$1.42M
Syndax Pharmaceuticals
Jun 20, 2018
Ten Percent Owner
Uninformative Sell
$1.36M
IMDZ
Immune Design
Dec 04, 2018
Informative Sell
1.65M
$2.17M
Pieris Pharmaceuticals
Sep 10, 2019
Ten Percent Owner
Informative Sell
224.50K
$5.03M
FPRX
Five Prime Therapeutics
Nov 13, 2020
Informative Sell
149.20M
$3.09M
CALA
Calithera Bio
May 26, 2020
Informative Sell
13.70M
$12.01K
Cytokinetics
Feb 18, 2020
See Explanaton of Responses
Informative Sell
16.92M
$352.31M
Merus
Oct 08, 2021
Ten Percent Owner
Informative Sell
31.22M
$9.99M
IDEAYA Biosciences
Feb 04, 2021
See Explanation of Responses
Informative Sell
835.36K
$5.95M
PRNB
Principia Biopharma
Kymera Therapeutics
Nov 06, 2023
Director, See Remarks and Footnotes
Informative Buy
5.30M
$222.67M
Olema Pharmaceuticals
Sep 14, 2023
Director, Ten Percent Owner
Informative Buy
14.82M
$73.67M
Eledon Pharmaceuticals
May 13, 2024
Ten Percent Owner
Uninformative Buy
$23.93M
CytomX Therapeutics
See Explanation of Responses
$4.76M
RAIN
Rain Oncology
Jan 29, 2024
Uninformative Sell
$0.00
Repare Therapeutics
Nov 17, 2023
Ten Percent Owner
Informative Buy
6.24M
$1.56M
Cullinan Management
Jan 19, 2023
Ten Percent Owner
Uninformative Sell
$807.15K
Third Harmonic Bio, Inc.
Oct 31, 2024
See Explanation of Responses
Informative Sell
14.30M
$2.05M
Structure Therapeutics, Inc. Sponsored ADR
May 12, 2023
Ten Percent Owner
Uninformative Sell
$169.24M
MoonLake Immunotherapeutics
Oct 08, 2024
Director, Ten Percent Owner
Informative Sell
100.00M
$64.16M
PNT
POINT Biopharma Global
Dec 20, 2023
Informative Sell
213.66M
$0.00
4D Molecular Therapeutics
Nov 13, 2024
See Explanation of Responses
Uninformative Sell
$739.33K
Gyre Therapeutics
Nov 19, 2012
See Explanation of Responses
Informative Buy
5.24M
$31.05M
CASC
Cascadian Therapeutics
Dec 22, 2015
Informative Buy
$207.39M
Dynavax
Sep 11, 2009
Ten Percent Owner
Informative Sell
3.35M
$208.29M
Neurocrine
Oct 14, 2011
See Explanation of Responses
Informative Buy
175.53K
$1.12B
Repligen
Jul 08, 2009
Indirect Beneficial Owner, Ten Percent Owner
Informative Sell
5.50K
$1.54B
EPRSQ
Epirus Biopharma
Dec 24, 2009
Informative Sell
2.54M
$13.66M
~ARRY
Array Biopharma
Jul 10, 2014
Uninformative Sell
2.25M
$596.76M
AMAG
Amag Pharmaceuticals
$14.15M
ARQL
Arqule
Jun 01, 2018
Informative Sell
5.18M
$15.43M
Rigel
Nov 20, 2013
Ten Percent Owner
Informative Sell
1.28M
$184.97M
TBRA
Tobira Therapeutics
Mar 25, 2014
Uninformative Sell
$47.19M
Curis
Apr 29, 2009
Indirect Beneficial Owner, Ten Percent Owner
Informative Sell
3.42M
$22.02M
~RPRX
Repros
$1.12M
Ligand Pharma
Mar 26, 2014
See Explanation of Responses
Informative Sell
5.48M
$14.52M
Palatin Technologies
Mar 03, 2014
Ten Percent Owner
Informative Sell
320.27K
$2.28M
ASTX
Astex Pharmaceuticals
Medicinova
Ten Percent Owner
$0.00
NPSP
NPS Pharma
List of latest transactions for each holding click on a transaction to see Bvf Partners LP Il's performance on stock

Bvf Partners LP Il insider profile FAQ

What is the percentage of profitable transactions made by Bvf Partners LP Il?
The percentage of profitable transactions made by Bvf Partners LP Il is 63%.
    What is the average return per transaction made by Bvf Partners LP Il?
    The average return per transaction made by Bvf Partners LP Il is 51.50%.
      What stocks does Bvf Partners LP Il hold?
      Bvf Partners LP Il holds: CCXI, CTIC, XENE, INFIQ, XOMA, GLYC, CNCE, SNDX, IMDZ, PIRS, FPRX, CALA, CYTK, MRUS, IDYA, PRNB, KYMR, OLMA, ELDN, CTMX, RAIN, RPTX, CGEM, THRD, GPCR, MLTX, PNT, FDMT, GYRE, CASC, DVAX, NBIX, RGEN, EPRSQ, ~ARRY, AMAG, ARQL, RIGL, TBRA, CRIS, ~RPRX, LGND, PTN, ASTX, MNOV, NPSP stocks.
        What was Bvf Partners LP Il’s latest transaction?
        Bvf Partners LP Il latest transaction was an Uninformative Sell of ―.
          What was Bvf Partners LP Il's most profitable transaction?
          Bvf Partners LP Il’s most profitable transaction was an Informative Buy of FPRX stock on November 26, 2019. The return on the trade was 467.90%.
            What is Bvf Partners LP Il's role in ChemoCentryx?
            Bvf Partners LP Il's role in ChemoCentryx is See Explanation of Responses.
              How can I follow the stock ratings of top corporate insiders?
              Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.